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Chronic obstructive pulmonary disease (COPD) which includes
chronic bronchit is and emphysema is a major cause of morbi-
d i t y  and  mor ta l i t y  i nindustrialised countries. An increas ing
prevalence of the disease has beenobserved in our  count ry
as well. Chronic bronchit is,  emphysema and bronchial asthma
are the major causes of obstruction to airf low from the lungs.
Unlike Bronchial asthma,t h e  a i r f l o w  l i m i t a t i o n  i n  C O P D  i s
pers is tent .  A  C IBA sympos ium in  1959 def ined chron ic  bron-
chitis, as a  c o n d i t i o n  o f  s u b j e c t s  w i t hchron ic  or  recurrent
excessive mucous secretionsi n  t h e b ronch ia l  s i t e  w i thou t  a
demonstrable cause, either local or general occurring most on
most of the days for at least three months in the, year during
last two years. Nat ional  Heart  lunga n d  B l o o d  I n s t i t u t e  i n
Intermittent positivepressure Breathing trial defined emphysema
morphologically as a condi t ion  o f  the  lung character ised by
abnormal pe rmanen t  en l a rgement  o ft h e  a i r s p a c e s  d i s t a l
t o the terminal bronchioles a c c o m p a n i e dby  des t ruc t i ve
changes  o f  t he  a l veo la r  wa l l s  and  w i thou t  obv ious  f i b ros i s
Pathogenesis
In  1964,  Er ikson showed that  congeni ta ld e f i c i e n c y  o f  
Alpha 1 antitrypsin (AAT) would lead to emphysema especially
in severe deficiency state associated with a proteaseinhibitor
phenotype z z (PI Z). The AAT level in PI Z disease is less than  
11 u mol. Even though, the serum antiprotease levels in common
he te rozygous  f o r  AAT  de f i c i ency  ( P I  MZ  Pheno type )  i s  l ow ,
cornpared to normal PI MM Phenotype,subjects w i t h  P I  M Z
Phenotype do not appear to be at increase risk of developing
COPD.  Th is  led  to  the protease –antiprotease theory of patho- 
genesis of emphysema. Tobacco-smoking is the most important 
risk factor associated w i t h  C O P D . T o b a c c o  s m o k e  a t t r a c t s  
alveolar macrophage (AM) and they cluster around the terminal
bronchioles. Alveolar macrophages activated by tobacco smoke
release neutrophil chemotactic factors such  as  l euko t r i ene  
B 4 ( L T B4 ),  complement components (C5a) and neutrophil che-
motactic factor. Thus circulating neutrophils from the blood stream
are attracted to the site where AM have already clustered around
the terminal bronchioles. Tobacco smoke causes activation of
neutrophils resulting inre lease of  Human Neutrophi l  E lastase
(HNE). HNE is capable of lysing elastin, collagen, proteoglycans,
f ibronect in  and lamin in  which form the interst i t ium of  lung.  In
a healthy individual, HNE is inactivated by alpha 1 - PI which
is Produced in the liver.The molecu lar  weight  o f  a lpha-1  P I
is 52000 kilodalton (KD) and this molecular size enables alpha-1
Pl to migrate to epithelial f ining f luid of lung from blood. The
binding of alpha-1 PI with HNE results in inactivation of HNE.
An  ac t i ve  meth ion ine  res idue  p resen t  i n  a l pha -  P I  mo l -
ecule  is  essent ia l  for  neutra l isat ion of  HNE.  Oxidants  present
in smoke oxidises methionine, thuspreventing the binding and
inactivation of HNE. In addition oxidants released by activated
neutrophils are also capable of  ox id is ing a lpha 1 -  P I .Thus
tobacco smoke, in addition to increasing the HNE burden in the
lower respiratory tract, causes inactivation of protein alpha - PI
which is  essent ia l  for  body’s  defense against  e lastases.  This
results in unopposed action of HNE on lung tissue leading to
destructive changes.
B r i t i sh  i nves t iga to r s hypo thes i sed  tha t  ch ron i c  a i r f l ow
obstruction is a late stage of chronic bronchitiswhich results
predominating fromcigarette smoking andis re fe r red  to  as
“B r i t i sh  hypo thes i s ” .  Howeve r ,  Du tchinvestigators proposed
that chronic bronchitis and emphysema were closely related to
bronchial asthma. Accord ing to  the  Dutch hypothes is ,  a i rway
narrowing developed as a primary abnormality in subjects who
were over-reactive in a manner analogous to allergic asthma to
a variety of allergic and other environmentalstimulants.
C l in i ca l  f ea tu res
Breathlessness on exertion, gradually progressing to breath-
lessness at  rest  is  the most  important  present ing symptom in
patients with emphysema.In chronic bronchitis, the predominant
symptom is cough,o f t en  w i th  ep i sodes  o fpersistent sputum
especially in winter months but without haemoptysis.Often these
patients may present with a history of wheeze. The breathlessness
i s  usual ly r e l a t i v e l y  c o n s t a n t  f r o m  d a y  t o  d a y  u n l i k e  t h e
day to day variabil ity observed in bronchial asthma,
On phys ica l  examinat ion,  hyper inf lat ion of  the chest  as
evidenced by reductionin  the cr icosternal  d is tance,b i l a t e r a l
respi ratory  indrawing of  suprac lav icu lar  fossae and intercosta l
spaces over the lower portion of the chest,l o s s  o f  abso lu te
card iac  du l lness  to  percuss ion and widening of  the  subcosta l  
angles are important findings.
In  order  to  descr ibe two types of  pat ients  wi th  chronic
bronchi t is  and emphysema,  two descr ipt ive  terms,  p ink  puf fer  
( T y p e  A )  a n d  b l u e  b l o a t e r  ( T y p e  B )  w e r e  u s e d .  B o t h  b l u e  
bloaters and pink puffers have similar degrees of airway obstru- 
ction. However, blue bloaters have marked central cyanosis, secon-  
dary polycythemia, suffusion of conjunctivae and face, elevated 
jugular venous pressure, ankle oedema,d i s tens i on  o f  f o rea rm 
veins and a fu l l  vo lume pulse.
hypoxemia and Co2
These  pa t i en t s  have  a r te r i a l  
retention with compensated respiratory acidosis. 
Their body weight tends to be higher than normal. Bird-f lapping 
t remor  ( t remor  of  the outst retched hands)  s ign i f ies  acute  CO2 
rentention.
On the other hand, the pink-puffers are often thin with a
body weight below average.These patients are very breathless. 
Central cyanosis is only minimal because profound arterial hypo- 
xemia is  rare C O2 retention, secondary polycythemiand cor -  
pulmonale are also rare.
Respiratory function  
The card ina l  feature  of  the COPD is  the demonstrat ion 
of airf low obstruction as revealed by a low FEV1/FVC ratio and 
l ow  Peak  Exp i ra to ry  F l ow  Ra te  ( PEFR ) .  I n  add i t i on ,  a l l  f l ow  
r a t e s  ( V E  m a x  2 5 % ,  5 0 % ,  a n d  7 5 % )  a r e  r e d u c e d  i n  C O P D .  
Typica l  f low vo lume curves  f rom a south Ind ian non-smoking 
normal  sub ject  and f rom a pat ient  w i th  COPD are  shownin      
in f igures 1 and 2.
F l G U R E  -  I
F L O W  – V O L U M E  L O O P  I N  A  N O R M A L
N O N  – S M O K I N G  S .  I N D I A N  S U B J E C T
PEFR  =  Peak  exp i r a to ry  f l ow  ra te
PIPR = Peak inspiratory flow rate
FVC = Forced v i ta l  capac i ty
RT = Res idua l  vo lume
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F IGURE –  2
F L O W  V O L U M E  L O O P  I N  A  P A T I E N T
WITH CHRONIC OBSTRUCTIVE AIRWAYS DISEASE
.
Lung volumes show hyperinflation as evidenced byan 
increase in to ta l  l ung  capac i t y  ( TLC )  and  the  r a t i o  o f  RV
(Residual Volume) to TLC.The d i f ference between the mult i -
ple breath TLC and single breath TLC will be more than 500ml,
suggesting that airtrapping is a feature of COPD.Both diffusing
capaci ty  (DLCO) ar id transfer coefficient (KCO) are reduced
in emphysema. Howeve r ,  DLCO  and  KCO  may  be  no rma l  i n
chronic bronchitis, possibly due tosecondary polycythemia.
Radiology
Chest radiographs may show flattened diaphragm, irregular
 rad io lucency of  the lungs.Lateral chest radiographs reveal an
 abnormal retrosternal space.These f ind ings may not be of
 diagnostic value in COPD.Examination of the width of the right
descending ( inter  -  lobar)  pu lmonary ar tery  on rout ine chest
 radiographs can detect pulmonary artery hypertension in COPD.
  Width of the descending branch of right pulmonary artery > 20 mm
 has been found to be an useful criterion for identifying patients
with pulmonary hypertension.
The presence of localised areas of abnormally low atten-
uation without surrounding walls or withvery thin ( > 1 mm
diameter) walls is the characteristic CT finding inemphysema
CT may show ev idence of  emphysema in  pat ients  wi th  normal
chest radiographs. Eventhough CT is currently the most accurate
method of diagnosing emphyserna in vivo, it has a very l imited
role in the clinical assessment of emphysema because of its cost.
However, CT may be useful in assessing symptomatic patients
with abnormal gas transfer without evidence of airway obstru-
ction on pulmonary function.It is also useful in the pre-operative
assessment of patients with Iargebullae being referred for bullo-
cromy. CT may also be indicated in the assessment of patients
with recurrent spontaneous pneumothorax.
Cardiovascular-Pulmonary interaction    
The pulmonary vascular bed is a low pressure, low-resist-
ance system, enabling it toaccommodate marked increasein
blood f low with  min imal  e levat ions in  pressure.  Three factors
influence pulmonary vascular resistance:
Pulmonary vascular resistance (mm Hg / L / min) =
 P u l m o n a r y  a r t e r y  p r e s s u r e  ( m m H g )  L e f t  a t r i a l  o r
wedge  p ressure  (mmhg)
Pulmonary  b lood f low (L /min) .
In  pat ients  wi th  COPD,  loss  of  vascular  sur face and a lveolar   
hypoxia induce pulmonary vasoconstriction that lead to augment  
pulmonary vascular resistance and pulmonary vascular pressure. 
Th is  resul ts  in  an increase in  the af ter load on r ight  ventr ic le
both at  rest  and at  exerc ise.  Hypoxemia is  the pr imary factor
that leads to pulmonary hypertension.Acidemia acts synergisti-
cally with hypoxemia in elevating pulmonary artery oressure and
vascular resistance, E leva ted  PaCO2 exerts an indirect effect by
reducing the PH. Untreated e levat ions in  pulmonary vascular
pressure in patientswith COPD have important prognostic impli-
cations. Patients with hypoxernic pulmonary vasoconstriction and
resting pulmonary hypertensionwith associated cor-pulmonale
have poor prognosis.
The election fraction (EF) which is the mathematical ratio
of stroke. volume to end-diastolic volume may be reduced eighter
due to a fall in stroke volume or an increase in diastolic filling.
Ejection fraction = Stroke volume
End-diastolic volume  
A reduced resting right ventricular EF can be utilised as a
marker for the presence of hypoxemia and pulmonary hypertension
in patients with COPD.A st rong inverse corre lat ion between
right ventricular EF and two indices of afterload namely, peak
pulmonary artery systolic pressure and pulmonary vascular resist-
ance was observed in patientsw i t h  C O P D . Thus, reduction
of EF in COPD patients can be considered as an early sign of
cor-pulmonale. In  conformity  wi th  th is ,  i t  had been observed
that in COPD patients with abnormal right ventricularEF, but
without cl inical signs of right heart fai lure, cor-pulmonale deve-
loped on fol low up.
Sleep studies  
Eventhough hypoxemia is  thought  to  be respons ib le  for
severe sequelae such as cor-pulmonale in patients with COPD.
some patients with COPD andr igh t  s i ded  hea r t  f a i l u re  have
only slightly abnormal awake arterial blood gases.However, these
patients have severe intermittent nocturnal hypoxemia and this
may be the in i t iat ing po int  for  the development  of  pu lmonary
hypertension. The proposed mechanism of nocturnal  oxygen
  desaturation and a common pattern of oxygen desaturation over
a n ight ’s  s leep in  pat ients  wi th  COPD are shownin figures 3
      and 4.
PROPOSED MECHANISM OF NOCTURNAL OXYGEN
DESATURATION IN COPD.
T r e a t m e n t
Long - term management of COPD involves the fol lowing :
1. Stopping smoking for l i fe.
Cigarette smoking is the single most important preventable
cause of COPD. Smoking cessation is therefore the most important
component of a treatment programme.Smoking cessation can
be tried either with drug treatment or with behavioral interve-
ntion. Drug therapy includes nicotine substitution with nicotin
polacri lex gum or transdermal patches. Clonidine has also bee
shown to augment nicotine substitution in al leviating withdrawal
symptoms.
F I G U R E - 4
A COMMON PATTERN OF  OXYGEN DESATURAT ION OVER 
A  N I G H T ’ S  S L E E P  I N  P A T I E N T  W I T H  C O P D .
2. Bronchodilators.
1. Theophylline
2 .  B2 agonists (Terbutaline, Pirbuterol)
3. Anticholinergics ( lpratropium bromide)
B e t a2 agonists and anticholinergics may induce short-term 
improvement in FEV1 after inhalation i n  p a t i e n t s  w i t h  C O P D .   
Eventhough the bronchodilator effect is very small,  patients may 
have symptomatic benefit.  Thus bronchodilator use may improve 
symptoms.
3. Corticosteroids.
The  r o l e  o f  i nha l ed  co r t i cos te ro i d s  i n  t he  management  
of COPD is controversial. Recent studies have suggested that
addition of anti- inflammatory therapy to regular bronchodilators
attenuates the decline of lung function in symptomatic patients
with COPD. However, the ongoing Eurpean Mult icentre Study
(Euroscop)  on inha led cort icostero ids  in  smokers  wi th  a i r f low
obstruction wil l  give an answer to the questionof the role of
corticosteroids in COPD.
4. Mucokinetic agents.
1  W a t e r
2   I o d i d e      
3 Oral expectorants (Guaifenesin)
 4  M u c o l y t i c s  ( A c e t y l c y s t e i n e ) .  
Although there is no clear evidence for therapeutic benefit
from mucokinetic agents, the chronic use of acetylcysteine may
protect the lungs from oxidant damage because of its antioxid-
ant properties.
5. Treatment of infective exacerbations.
Empiric use of broad spectrum antibiotics is recommended
for the acutely deteriorating patients with neutrophil ic sputum
despite no overt sign of pneumonia.
6 Alpha 1- antitrypsin replacement
a) Alpha 1 – antitrypsin (Injection, aerosol)
b)  Danazol (200 mg three times a day)
More studies  are r e q u i r e d  b e f o r e  t h e s e  d r u g s  c a n  b e
  prescr ibed for  the t reatment  o f  COPD>
7. Pulmonary vasodilators
a). Alpha – adrenergic blockers
(Prazosin, urapidil)
b). Calcium channel blockers
(Nifedipine, Nitrendicine)
c ) . Angiotensin Converting Enzyme inhibitors
(Captorpril, Enalapril)
d). Prostaglandins
1. E 1 ,  E 2
2. Prostacycline (Prostaglandin 12 )
An ideal pulmonary vasodilator drug is yet to be identified.
8.  A lmitr ine b ismesylate
Almitrine is reported to increase PaO2 n d  r e d u c e  P a C O2 in 
patients with COPD.
9. Diuretics
Diuretics may be required in congestive cardiac failure or 
cor pulmonale.
10.  Dig i ta l is
Dig i ta l is  is  the drug of  choice for  le f t  ventr icu lar  fa i lure 
or Supraventricular tachyarrhythmias. However, d ig i ta l is  has
not been shown to improve right ventricular functioneither at
rest or during exercise, except
left ventricular failure.
i n  t h e  p r e s e n c e  o f  c o n c u r r e n t   
T h e  p o s s i b i l i t y  t h a t  d i g o x i n  m a y  h a v e   
favourable  ef fects  when used in  combinat ion wi th  other  medi -  
cat ions such as theohypl l ine,  vasodi lators ,  se lect ive B.  –  adre-  
nergic agentsand oxygen requires further study.
11. Phlebotomy
Phlebotomy should  be reserved for  use as  an ad junct ive  
therapy in the acute management of the markedly polycythemic  
patients who has an acute decompensation of cor pulmonale.
12. Prevention of influenza
S ince  pa t i en t s  w i th  COPD  a re  a t  i n c reased  r i s k  f r om
influenza and its sequelaeincluding respiratory fa i lure,  they
shou ld  be  vacc ina ted  w i th  an  i nac t i va tedinfluenza vaccine
currently circulating.
13. Exercise training
Since fatigue of respiratory muscles is an important feature
of COPD, inspiratory muscle training has been shown to improve
exercise endurance and 12-minute walking distance.
14. Nutritional therapy to reverse malnutrition in emphysematous
patients.
1 5 .  L o n g - t e r m  h o m e  o x y g e n  t h e r a p y
Two land mark studies, theNa t i ona l  Hea r t ,  Lung  and
Blood Institute’s Nocturnal Oxygen Therapy Trial( N O T T )  a n d
the Brit ish Medical Research Council  (BMRC) multicentreial
have demonstrated that  oxygen improved surv ival  in  se lected
patients with advanced COPD.BMRC study compared 15 hours
of continuous oxygen including hours of sleep with nooxygen
in a randomly assigned patients.T h e  N O T T  s t u d y  c o m p a r e d
oxygen for  12 hours  a  day (nocturna l  group)  w i th  24 hours  a
day  ( con t i nous  g roup )  i n  pa t i en t s  w i th  advancedCOPD.
C O M P O S I T E  G R A P H  O F  T H E  B M R C  A N D  T H E
N H L B I  N O T T  S T U D Y .
T I M E  ( m o n t h s )
The continuous oxygen therapy group actually received oxygen for an
average of  19.4  hours  a  day.Both studies  enro l led pat ients
with advanced COPD with signif icant hypoxemia, who werein
stable state and wereotherwise receiving good treatment for
airf low obstruction.I n  t he  BMRC  s tudy ,  t he  oxygen  the rapy
group had improved survival,which became apparent in males
after 500 days of the study had elapsed.I n  t h e  N O T T  t r i a l ,
a  c lear  survival  benef i t  wasobserved in  cont inuous oxygen
therapy group compared to only nocturnal oxygen therapy group.
The combined results of these studies are summarised in figure 5.
Patients who received no oxygenhad a surv ival  of  only  30%
in  f i ve  yea r s .  On  the  o the r  hand ,  BMRC  pa t i en t s  who  had
received oxygen therapy for 15h o u r s  p e r  d a y  h a d  s i m i l a r
su rv i va l  compared  to  NOTT  t r i a l  pa t i en t s  who  had  rece i ved
nocturnal oxygen for 12 hours per day. The best results were
in NOTT trial patients who receivedoxygen for  approximately
1 9 4 hours  per  day.  Thus,  in  COPD pat ients ,  no oxygen is
bad,  some oxygen is  better  and cont inuous oxygen is  best .
Guideli l Ies for home oxygen for patients with advanced COPD
is given in Table 1.
T a b l e  I
General Prescribing Guidel ines for Home Oxygen
for Patients with Advanced COPD
Patient Selection Criteria:
1. Stable course of disease on optiumindicated medical
therapy, eg.,bronchodilator, antibiotics, corticosteroidess
2 .  A t  l eas t  two  a r te r i a l  b l ood  gasdeterminat ions whi le
breathing air for atleast 20 minutes.
3. Room a i r  PO2 consistently 55, or consistently 55 - 59 +
cor pulmonale cl inically diagnosed or hematocrit 55%.
4. Normoxic patients in whom less dyspnea and increased
exercise is demonstrated with oxygen.
Oxygen Dose :
1. Cont inuous  f low by double or single nasal cannulae.
2. By demand system w i t h  d e m o n s t r a t i o n  o f  a d e q u a t e
3 3
oxygen saturation.
3 .  L o w e s t  l i t e r  f l o w  t o  r a i s e  P O2 t o  6 0 - 6 5  o r  o x y g e n
saturat ion  to  88-94%.
4.  Increase basel ine l i ter  f low by 1 L  dur ing exerc ise and
sleep.
Oxygen systems
Oxygen is furnished in three forms : compressed gas oxygen,
l iquid oxygen and oxygen concentrator. Advantages and disad-
vantages of home oxygen systems are given in Table 2.
T a b l e  2
Advantages and Disadvantages  o f  Ava i lab le  Home Oxygen
Systems
LIQUID PORTABLE CONCENTRATORS COMPRESSED GAS
Advantages :
1. Light weight 1. Lower cost 1. L o w e r  c o s t  i n
general (cost may
equal  l iquid in
continuous use
situations).
2. Long range 2.  Convenient  at 2. Widespread
portable canister home availability
3 .  Most  pract ica l 3 .  Att ract ive
ambulatory system equipment
4.  Va luable  for 4. Widespread
pulmonary availability
rehabilitation
5 .  1 0 0 %  o x y g e n  a t
all flow rates
Disadvantages :
1 .  M o r e  e x p e n s i v e  1 .  E l e c t r i c i t y 1. Multiple tanks
than concentrators required necessary for
used alone ambulation
unless transfill-
ing can be done
at home
2. Not available in 2. May need back-up 2. Frequent deliver-
small or rural tank system ies needed
communities
3. Not portable: 3. Heavy and unsi-
does not assist ghtly tanks; not




Several means of oxygen delivery have been available including nasal
catheters, various permutations of masks,nasal cannulas and
transtracheal catheters. Most patients on long - term oxygen
therapy can be managed via continuous flow nasal cannulas.
The most common flow setting is 2 L/min and this raises the
F l O2 of room air from 20.9% to about 27% which is sufficient
to improve oxygen saturation to 90% or above in most patients with
COPD. However, only a small portion of this continuously
flowing oxygen is actually available for alveolar ventilation.
TO overcome this problem of oxygen: wastage, oxygen conserving
devices ate developed. Three distinct categories ofoxygen
conserving devices are currently available: Transtracheal oxygen
delivery, reservoir canulas (the oxymizer and oxymizer pendant)
and Electronic - demand oxygen delivery devices.
16. Home ventilatory support
Home ventilatory support should be considered for those
patients with frequent decompensation of respiratory failure to
prevent a fatal episode, in those who fail to wean alter an
acute exacerbation and where PaO2 cannot be maintained over
7. 0 Kpa (52 mmg) without excessive hypercapnia (PaCO2 10. 0
Kpa or 75 mm Hg.) Respiratory muscle rest in the form of
assisted ventilation would relievechronic fatigue and produce
a sustained correction of hypercapnia. Themethods available
are intermittent negative pressureventilation and intermittent
positive pressure ventilation. Negative pressure ventilation by
tank respirator, cuirasshell or pneumosuit iscumbersome and
uncomfortable. It has been reported recently that nasal intermittent
positive pressure ventilation can be used effectively athome
during sleep in selected patients with COPD.Future studies
cucomparing domiciliary ventilation with long - term oxygen the-
rapy are required to clarify the role of domiciliary ventilation
in the treatment of COPD.
Lung Transplantation     
Lung t ransp lantat ion  has  been found to  be  an  e f fect ive
modal i ty  for  the  management  o f  end s tage pu lmonary  d isease.
The most signif icant factorres t r i c t ing  the  app l i ca t ion  o f  lung
transp lantat ion  i s  donor  ava i lab i l i ty .  Donor  se lect ion  and rec i -
p ient  c r i ter ia  are  g iven in  Tab les  3  and 4 .
Table 3
General Donor Selection Guidelines
1.  Age  < 65  fo r  lung ;  <  45  fo r  hear t - lung .
2 .  No  severe  chest  t rauma or  in fect ion .
3 .  C lear  chest  X - ray  (except ion  may occur ) .
4 .  No  pro longed card iac  ar rest  (hear t - lung on ly ) .
5 .  M in imal  pu lmonary  secret ions .
6 .  Negat ive  H IV  screen.
7 .  ABO compat ib i l i ty .
8 .  S imi la r  to ta l  lung  capac i t ies
T a b l e  4     
General Recipient Guidelines
1. Untreatable end-s tage pu lmonary  vascu lar  d iseaseo f  a n y
aetiology.
2. No other signif icant medical.  diseases.
3 .  Substant ia l  l im i ta t ion  o f  da i ly  act iv i t ies .
4 .  L imi ted  l i fe  expectancy ,
5 .  Ambulatory  wi th  rehab i l i ta t ion  potent ia l .
6. Acceptable nutrit ional status.
7. Satisfactory psychosocial profile and emotional support system.
Contraindications for lung transplantation are listed in Table 5.
T a b l e  5
Contraindications for Lung Transplantation
1. Active extra pulmonary infection.
2. Significant disease of other organ systems.
3. Current cigarette smoking.
4. Poor nutritional status.
5. Post rehabilitation potential. 
6. Significant psychosocial problems,
Substance abuse,or history of medical non-compliance
Lung Transplantation :Report of the ATS Workshop on Lung
Transplantation Amer Rev Respir Dis : 1993; 147 : 772 – 76.
Transplant procedures available for COPD patientsare           
Heart– Lung transplantation, Double lung and single lung Tran-
splantations. Transplantation procedures that are applicable to dis-
eases states are provided in Table 6.
T a b l e  6
Transplantation procedure by Disease state
Transplantation Disease state
procedure
Heart – Lung Eisenmenger’s syndrome with irreparable cardiac
defect ;  pu lmonary  hyper tens ion  wi th  Cor  pu l -
m o n a l e ;  e n d - s t a g e  l u n g  d i s e a s e  w i t h  c o n -   
current severe cardiac disease,
Double Lung Cystic fibrosis; generalised bronchiectasis some
patients with COPD.
Single Lung Rest r i c t ive  f ib ro t i c  lung  d i sease ;  E i senmenger ’s   
syndrome with  repa i rab le cardiac anomaly;
son ic  pat ients  w i th  COPD;  pr imary  pu lmonary
hypertension.
Agency for Heart Care Policy and Research (USA) states.
“lung transplantation has evolved aclinical procedure achieving
a favourable risk– benefit ratio and acceptable 1 – and 2 – year
survival rates"
Pulmonary Rehabilitation    
Pulmonary rehabilitation was defined bythe American
College of Chest Physicians committee on Pulmonary Rehabili-
tation as an art of medical practice wherein anindividually
tailored, multidisciplinary programme is formulated which through
accurate diagnosis, therapy, emotional support,and education,
stabilizes or reverses both the physio–and psychopathology of
pulmonary diseases and attempts to return thepatient to the
highest possible functional capacity allowed by his pulmonary
handicap and overall life situation.
Components and benefits ofpulmonary rehabilitation are
listed in Tables 7 and 8.
Table 7
Components of Pulmonary Rehabilitation
General
1. Patient and family education
2. Proper nutrition including weight control
3. Avoidance of smoking and other inhaled irritants




















  3. Chest percussion and posturaI drainage
4. Deliberate coughing and expectoration
Exercise conditioning
Occupational therapy
1. Evaluate activities of daily living
2. Outline energy-conserving maneuvers
Psychosocial rehabilitation
Vocational rehabilitation
T a b l e  8
Demonstrated Benefits of Pulmonary Rehabilitation
1. Reduction in respiratory symptoms.
2. Reversal of anxiety and depression and improved ego strength.
3. Enhanced ability to carry out activities of daily living.
4. Increased exercise ability.
5. Better quality of life.
6. Reduction in hospital days required.
7. Prolongation of life in selected patients, i.e., use of cont-
inuous oxygen in patients with severe hypoxemia.
Prognosis
Factors related to survival are listed in Table 9.
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Factors related to survival
Factors Related Positively to Survival *
1. FEV 1
2. P a O2    
39
3. Reversibility of airflow obstruction following inhaled
4. Exercise capacity.
5 .  D i f fus ing capac i ty .    
6. Vital capacity.
7. Atopy.
Factors Related Negatively to Survival * *
1.  Age
2. Decrease in FEV1 on serial testing.
3 .  R e s t i n g  h e a r t  r a t e .
4 .  PaCO2
5. Pulmonary artery pressure/cor pulmonale.
6. Total lung capacity.
7. Perceived physical disability/dyspnea.
8. Continued smoking.
9. Malnutrition/weight loss.







The higher the value or presence of the factor, the better
the survival
The higher the value or presence of the factor, the poorer
the survival.
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